-
公开(公告)号：US20230272104A1
公开(公告)日：2023-08-31
申请号：US18015690
申请日：2021-07-16
发明人： Xiaohu Fan , Zhe Zhou , Qiuchuan ZHUANG , Xu Fang , Hongbo PAN , Min Wei , Jianrui ZHU
IPC分类号： C07K16/28 , C07K14/725 , A61P35/00
CPC分类号： C07K16/2887 , C07K14/7051 , A61P35/00 , C07K2317/565 , C07K2317/569 , C07K2317/20 , C07K2319/03 , C07K2319/02
摘要： The present disclosure provides single domain antibodies that bind to CD20, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
-
公开(公告)号：US20230257475A1
公开(公告)日：2023-08-17
申请号：US18015505
申请日：2021-07-16
发明人： Xiaohu Fan , Zhe Zhou , Hongbo PAN
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , C12N15/63 , A61P35/02
CPC分类号： C07K16/2887 , C07K16/2896 , C07K14/70517 , C07K14/7051 , C07K14/70596 , C12N15/63 , A61P35/02 , C07K2319/03 , C07K2317/569 , C07K2317/565
摘要： The present disclosure provides chimeric antigen receptors targeting CD20, CD19 and/or CD22. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
-
公开(公告)号：US20230250184A1
公开(公告)日：2023-08-10
申请号：US18015506
申请日：2021-07-16
发明人： Xiaohu Fan , Zhe Zhou , Qiuchuan ZHUANG , Xu Fang , Yue HAN , Youguo PENG , Hefei HOU
CPC分类号： C07K16/2896 , C12N15/63 , A61P35/00 , C07K2317/565 , C07K2317/569 , C07K2319/02 , C07K2319/03 , C07K2317/53
摘要： The present disclosure provides single domain antibodies that bind to CD22, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
-
公开(公告)号：US11827713B2
公开(公告)日：2023-11-28
申请号：US16626721
申请日：2018-06-27
发明人： Xiaohu Fan , Qiuchuan Zhuang , Lei Yang , Pingyan Wang , Qingyan Li
IPC分类号： C07K16/28 , A61P35/00 , A61K39/00 , C07K14/765
CPC分类号： C07K16/2896 , A61P35/00 , C07K14/765 , C07K16/2809 , C07K16/2878 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/02 , C07K2319/30
摘要： Provided is a chimeric antibody immune cell engager comprising a target cell binding domain that specifically binds to an antigen on a target cell, and an immune effector cell binding domain comprising an antigen-binding fragment that specifically binds to an antigen on an immune effector cell. Also provided are pharmaceutical compositions, kits and methods of treatment.
-
公开(公告)号：US20230192883A1
公开(公告)日：2023-06-22
申请号：US18015508
申请日：2021-07-16
发明人： Xiaohu Fan , Zhe Zhou , Qiuchuan ZHUANG , Xu Fang , Yue HAN , Youguo PENG , Manman LU
CPC分类号： C07K16/2896 , A61P35/00 , C12N15/63 , C07K2317/20 , C07K2317/565 , C07K2317/567 , C07K2319/02 , C07K2319/03
摘要： The present disclosure provides single domain antibodies that bind to CD19, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
-
公开(公告)号：US11564945B2
公开(公告)日：2023-01-31
申请号：US16474735
申请日：2017-12-29
发明人： Xiaohu Fan , Qiuchuan Zhuang , Pingyan Wang , Lei Yang , Xiujun Zheng , Jiaying Hao , Shaobo Liu
IPC分类号： A61K35/17 , C07K14/725 , C07K16/30 , C07K16/32 , C12N5/0735 , C12N5/0775 , C12N15/62 , A61K45/06
摘要： Disclosed herein is a novel chimeric antigen receptor and use thereof. The novel chimeric antigen receptor consists of a signal peptide, an antigen binding domain, a transmembrane region, and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane region. Nucleic acid sequences of various chimeric antigen receptors are separated and purified and provided is a chimeric antigen receptor and a CAR-T cell which are specific for a CD19 malignant tumor antigen. In the malignant tumor killing test of hematological cell lines, the ability of immune cells to target and recognize tumor cells is significantly enhanced, and the killing activity against tumor cells is also enhanced.
-
公开(公告)号：US20240316201A1
公开(公告)日：2024-09-26
申请号：US18276703
申请日：2022-02-25
发明人： Xiaohu Fan , Jie Mao , Qiuchuan ZHUANG , Changjiang Zhang
IPC分类号： A61K39/00 , A61P35/00 , C07K14/52 , C07K14/54 , C07K14/705 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/86
CPC分类号： A61K39/464474 , A61K39/4611 , A61K39/4631 , A61P35/00 , C07K14/52 , C07K14/5434 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/303 , C12N5/0636 , C12N15/86 , C07K2317/622 , C07K2319/03 , C07K2319/30 , C12N2740/15043
摘要： An immune effector cell expressing an exogenously introduced p40 subunit of IL-12; an exogenously introduced ligand of CCR7 (such as CCL-19 and CCL-21); and a functional exogenous receptor (such as a chimeric antigen receptor) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain.
-
公开(公告)号：US20220073643A1
公开(公告)日：2022-03-10
申请号：US17419203
申请日：2019-12-27
发明人： Liusong Yin , Tielin Zhou , Zhuo Fang , Yong Liu , Qiuchuan Zhuang , Bo Wu , Xiaohu Fan , Qingshan Zhang , Dan Zhao , Jie Mao
摘要： Described herein are binding moieties, such as antibodies, that specifically bind Claudin18.2, and chimeric antigen receptors comprising such binding moieties. Further provided are engineered immune cells (such as T cells) comprising anti-Claudin 18.2 chimeric antigen receptors. Also disclosed are methods of treating Claudin18.2-expressing tumor or cancers using the binding moieties, chimeric antigen receptors and engineered immune cells.
-
公开(公告)号：US20190225668A1
公开(公告)日：2019-07-25
申请号：US16329739
申请日：2017-08-31
发明人： Qiuchuan Zhuang , Xiaohu Fan , Lei Yang , Pingyan Wang
IPC分类号： C07K14/705 , A61K35/17 , A61P35/02 , C12N15/62 , C12N15/86
摘要： The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.025 秒)
